zoxazolamine

**Zoxazolamine** is a centrally acting skeletal muscle relaxant and uricosuric agent that was synthesized in 1953 and introduced to clinical use in 1955, but it has since been withdrawn from the market due to hepatotoxicity[3][7]. The compound is metabolized by cytochrome P450 enzymes[1]. Zoxazolamine has been used clinically to reduce muscle tone and spasticity, for example in cerebral palsy, and demonstrated uricosuric effects[2][5]. Its mechanism of action involves activation of small conductance calcium-activated potassium channels (such as small conductance calcium-activated potassium channel protein 2), contributing to its muscle relaxant effect[7]. The precise mechanism for its muscle relaxation is not fully understood[5]. Zoxazolamine is no longer approved for use in humans but has been used in research to assess CYP450-mediated metabolism and drug action in rodents[6].

Brand names

ContrazoleDeflexolFlexinMiazolUri-BoiZoxamineZoxine

Other names

2-amino-5-chlorobenzoxazole5-chloro-2-benzoxazolamine